Ketamine Clinics Are Booming in 2026: What the Evidence Actually Shows and Who Should Avoid Them

Ketamine was once an anesthetic used mainly in hospitals. In 2026, ketamine clinics are booming, offering infusions for depression and other conditions. Drug companies are rushing to bring ketamine medicines to market (NYT, 2026). The demand is real, but the evidence is narrower than the marketing suggests.

Key Takeaways

• Drug companies are rushing ketamine medicines to market in 2026 (NYT, 2026).
• Esketamine (Spravato) is FDA-approved for treatment-resistant depression; clinic infusions often use off-label racemic ketamine (FDA).
• Evidence supports rapid symptom relief in some treatment-resistant cases, but durability and long-term safety are uncertain (NIMH; clinical reviews).
• Ketamine is not appropriate for people with uncontrolled hypertension, certain heart conditions, or active substance use (clinical guidance).

What Does the Evidence Actually Support?

Esketamine nasal spray is FDA-approved for treatment-resistant depression, with data showing rapid improvement in some patients (FDA). Off-label ketamine infusions have promising but less rigorous evidence. Most benefits appear within hours to days, but durability varies and relapse is common without maintenance (NIMH; clinical reviews).

Citation capsule: Esketamine is FDA-approved for treatment-resistant depression; off-label infusions have promising but less rigorous evidence, with variable durability (FDA; NIMH).

How Do Ketamine Clinics Work?

Clinics typically offer a series of IV infusions over two to three weeks, followed by maintenance. Monitoring includes blood pressure and mental status during and after infusion. Costs are often out of pocket, and insurance coverage is inconsistent (clinical guidance).

Citation capsule: Clinics offer IV infusion series over 2-3 weeks with monitoring; costs are often out of pocket (clinical guidance).

Who Should Avoid Ketamine?

Ketamine raises blood pressure and heart rate. People with uncontrolled hypertension, significant cardiovascular disease, active psychosis, or substance use disorders are generally not candidates. Pregnancy is a contraindication. A thorough medical and psychiatric evaluation is essential (clinical guidance).

Citation capsule: Contraindications include uncontrolled hypertension, cardiovascular disease, active psychosis, substance use disorders, and pregnancy (clinical guidance).

What Are the Risks?

Short-term risks include dissociation, nausea, blood pressure spikes, and sedation. Long-term concerns include bladder toxicity (ketamine cystitis), cognitive effects, and dependence with repeated use. The long-term safety profile in clinic settings is still being studied (clinical reviews).

Citation capsule: Risks include dissociation, BP spikes, bladder toxicity, cognitive effects, and dependence with repeated use (clinical reviews).

How Should Someone Decide?

Ketamine is best considered after standard treatments have failed, under psychiatric supervision, with clear goals and monitoring. It is not a first-line fix for ordinary sadness, and it does not replace therapy or ongoing care (NIMH; clinical guidance).

Citation capsule: Ketamine is for treatment-resistant cases under psychiatric supervision, not first-line care for ordinary sadness (NIMH; clinical guidance).

Frequently Asked Questions

Is ketamine FDA-approved for depression?

Esketamine (Spravato) is FDA-approved for treatment-resistant depression; IV ketamine infusions are off-label (FDA).

How fast does it work?

Some patients improve within hours to days, but durability varies (NIMH).

Is it safe long-term?

Long-term safety is still being studied; bladder and cognitive risks exist (clinical reviews).

Does insurance cover it?

Coverage is inconsistent; many patients pay out of pocket (clinical guidance).

Conclusion

Ketamine can be a lifeline for treatment-resistant depression, but it is not a shortcut. Careful screening, medical supervision, and realistic expectations are essential.

Sources

• NYT. Why Drug Companies Are Rushing to Market Ketamine Medicines. 2026. Retrieved 2026-10-26. https://www.nytimes.com
• FDA. Spravato (esketamine) labeling. Retrieved 2026-10-26. https://www.fda.gov
• NIMH. Ketamine for Depression. Retrieved 2026-10-26. https://www.nimh.nih.gov